Literature DB >> 15135732

XPC lymphoblastoid cells defective in the hMutSalpha DNA mismatch repair complex exhibit normal sensitivity to UVC radiation and normal transcription-coupled excision repair of DNA cyclobutane pyrimidine dimers.

Katsutoshi Kobayashi1, Mark O'Driscoll, Peter Macpherson, Leon Mullenders, Maaike Vreeswijk, Peter Karran.   

Abstract

Nucleotide excision (NER) is generally considered to comprise two partially distinct subpathways. Global genomic repair (GGR) removes damage from the genome overall and transcription-coupled repair (TCR) selectively excises damage from transcribed DNA. Cells from individuals belonging to xeroderma pigmentosum (XP) complementation group C are defective in GGR but retain a functional TCR pathway. DNA mismatch repair (MMR) corrects replication errors but can also process DNA damage. It has been suggested that the essential hMutSalpha and hMutLalpha MMR protein complexes are also required for effective excision of UV-induced cyclobutane pyrimidine dimers (CPD) by TCR. We have combined an MMR and an XPC defect in a human lymphoblastoid cell line. The MMR-defective XPC cells were defective in the hMutSalpha mismatch recognition complex that comprises hMSH2 and hMSH6. They were not detectably more sensitive to killing by UV than their MMR proficient counterparts and were able to excise CPDs from an actively transcribed DNA strand. We conclude efficient TCR does not depend on a functional hMutSalpha complex.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135732     DOI: 10.1016/j.dnarep.2004.02.007

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  2 in total

Review 1.  Involvement of mismatch repair in transcription-coupled nucleotide excision repair.

Authors:  Katsutoshi Kobayashi; Peter Karran; Shinya Oda; Katsuhiko Yanaga
Journal:  Hum Cell       Date:  2005-09       Impact factor: 4.174

Review 2.  Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies.

Authors:  Nawar Al Nasrallah; Benjamin M Wiese; Catherine R Sears
Journal:  Front Oncol       Date:  2022-04-21       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.